- STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trialsAstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.STAT · 1mo ago↗ source
- City banks nearly $100M for next-gen RNAi drugs<figure><div><img src="https://imgproxy.divecdn.com/pxC2yW1qZhMv8FFHGtViPA2KryY3_Pfu7kxPvvCensY/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjk3MDM0MzI5LmpwZ…BioPharma Dive · 1mo ago↗ source
- Roche stakes $700M on Nurix’s protein-degrading drug<p>Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.</p>